{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FL&page=2", "query": { "condition": "FL", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FL&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T19:51:53.565Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04537715", "title": "Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "All Malignancies", "Advanced Malignancies", "Hematologic Malignancy", "Solid Tumor", "Follicular Lymphoma (FL)", "Non-Hodgkin Lymphoma (NHL)", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Epithelioid Sarcoma (ES)", "Synovial Sarcoma", "Renal Medullary Carcinoma", "Mesothelioma", "Rhabdoid Tumor" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-04-23", "completion_date": "2023-04-03", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 7, "location_summary": "Encinitas, California • Los Angeles, California • Chicago, Illinois + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04537715" }, { "nct_id": "NCT04594642", "title": "A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "AZD0486 IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 226, "start_date": "2021-03-02", "completion_date": "2028-06-19", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 9, "location_summary": "Tampa, Florida • Louisville, Kentucky • New Brunswick, New Jersey + 6 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04594642" }, { "nct_id": "NCT03893682", "title": "A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "CG-806", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2019-04-30", "completion_date": "2024-05-17", "has_results": false, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 30, "location_summary": "Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893682" }, { "nct_id": "NCT00772668", "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphoma", "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "17 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2009-09-25", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2017-12-11", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772668" }, { "nct_id": "NCT02875548", "title": "A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma (DLBCL)", "Follicular Lymphoma (FL)", "Synovial Sarcoma", "Epitheliod Sarcoma (ES)", "Mesothelioma", "Advanced Solid Tumors", "Renal Medullary Carcinoma", "Non-Hodgkin Lymphoma (NHL)" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2016-08-30", "completion_date": "2025-09-26", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 11, "location_summary": "Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Santa Fe", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02875548" }, { "nct_id": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-08-07", "completion_date": "2031-07-08", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792825" }, { "nct_id": "NCT07128641", "title": "Odronextamab in Low Tumor Volume Advanced FL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Lymphoma" ], "interventions": [ { "name": "Odronextamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gottfried von Keudell, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-09-08", "completion_date": "2028-01-02", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07128641" }, { "nct_id": "NCT01799889", "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Non-FL Indolent Non-Hodgkin's Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Entospletinib MM", "type": "DRUG" }, { "name": "Entospletinib SDD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2013-03-14", "completion_date": "2020-01-30", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01799889" }, { "nct_id": "NCT05255354", "title": "Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Follicular Lymphoma", "Diffuse Large B Cell Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "ClonoSEQ", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Adaptive Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2022-06-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05255354" }, { "nct_id": "NCT03460977", "title": "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer (mCRPC)", "Small Cell Lung Cancer (SCLC)", "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "Mervometostat (PF-06821497)", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 453, "start_date": "2018-04-17", "completion_date": "2029-07-07", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-06-25T19:51:53.565Z", "location_count": 46, "location_summary": "Tucson, Arizona • Anaheim, California • Duarte, California + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03460977" } ] }